Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
Decision snapshot: AMGN stock price vs RVTY: inconclusive Relative valuation is incomplete for this pair. Review the available filing metrics before drawing a conclusion.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at RVTY's multiple
Needs RVTY P/E.
Implied fair value · at AMGN's multiple
Needs AMGN P/E.
Price unavailable
Metric by metric
Where each company leads, and how wide the gap is.
Growth edge
Reported gross margin
Operating income + D&A
Lower is better
Not comparable
Lower leverage
Statements
Annual statements in reported currencies, with calculations and source evidence.
Values retain reported currencies and share bases. Select a figure to inspect its period, calculation and filing inputs. Differences require compatible units and periods.
Explore enterprise value and market valuation multiples in the valuation sections.
Trendline
11 period-end years of reported revenue, earnings, and margins. Periods and currencies are shown with the data.
Price framework
USD market cap plus reported borrowing debt, less cash and equivalents. This EV proxy excludes investments, preferred stock and noncontrolling-interest adjustments.
Complete market value, debt and cash evidence is required for enterprise value.
Complete market value, debt and cash evidence is required for enterprise value.
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
Amgen Inc. · implied price per share
Bear
$98.66
Base
$130.87
Bull
$172.82
REVVITY, INC · implied price per share
Debt and bridge-cash inputs are required to translate enterprise value into equity value.
Balance sheet health
Inspect reported liquidity and leverage alongside historical financial-health checks.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Not enough data to score either balance sheet.
Cash excludes investments. EBITDA is an operating-income-plus-D&A proxy. Missing borrowing categories remain unavailable; select a value to inspect its inputs.
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
REGENERON PHARMACEUTICALS, INC.
AMGN vs REGN
BIOGEN INC.
AMGN vs BIIB
VERTEX PHARMACEUTICALS INC / MA
AMGN vs VRTX
Gilead Sciences, Inc.
AMGN vs GILD
Moderna, Inc.
AMGN vs MRNA
Eli Lilly and Company
AMGN vs LLY
AGILENT TECHNOLOGIES, INC.
AMGN vs A
WATERS CORP /DE/
AMGN vs WAT
BIO-RAD LABORATORIES, INC.
AMGN vs BIO
METTLER TOLEDO INTERNATIONAL INC/
AMGN vs MTD
DANAHER CORP /DE/
AMGN vs DHR
THERMO FISHER SCIENTIFIC INC.
AMGN vs TMO
LLM-powered synthesis
An explanation of the financial evidence. Check its snapshot date against the figures above.
This explanation uses an earlier data snapshot or evidence version. Review its generation date and the current figures, or refresh after signing in.
If you believe AMGN’s superior margins, ROIC, and growth can persist while the market rerates it closer to the P/E-implied valuation, then AMGN looks like the better relative-value buy versus RVTY because the operating fundamentals are materially stronger than RVTY despite a more modest current multiple.
AMGN’s current price of $378.87 sits well below the P/E-implied value of $792.07, implying 109.1% upside, but it also falls inside the broader RVTY-implied range and above the DCF range. The gap is driven more by AMGN’s much lower P/E multiple than by its P/S or EV-based multiples, which are closer to RVTY’s on some measures.
Supporting Metrics
